#United States #New York #Class Action #Securities #Regeneron

Regeneron Pharmaceuticals Class Action Lawsuit

Overview
Levi & Korsinsky, LLP has announced that a class action securities lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This action stems from alleged fraud that specifically impacted investors during the period from November 2, 2023, to October 30, 2024. Investors who were affected are encouraged to seek more information and discuss their legal rights with the firm before the deadline of March 10, 2025.

Allegations Made in the Lawsuit

The class action lawsuit claims that Regeneron made misleading statements or concealed crucial information regarding the company’s financial practices. Among the allegations are that Regeneron:
1. Paid credit card fees to distributors with stipulations that they wouldn't charge Eylea customers excessive fees when using credit cards.
2. Used these payments to reduce the prices charged to customers purchasing Eylea with credit cards, creating an unfair pricing advantage.
3. Misrepresented Eylea sales figures, leading to inflated market perceptions of the product's success.
4. Falsely reported pricing information to federal agencies, violating the False Claims Act through misrepresentation.

Impact on Investors

The lawsuit seeks to recover losses for those who bought Regeneron shares during the aforementioned period. The plaintiffs argue that the falsified information led to a serious misinterpretation of the company's financial health and operational viability. As a result, investors incurred significant losses once the reality of the situation became clear.

Next Steps for Affected Investors

Investors who suffered losses during this timeframe have until March 10, 2025, to act. They can request to be appointed as lead plaintiffs in this case, although participation in any potential recovery does not require this designation.

Contact Information

For those who might be affected, the law firm, Levi & Korsinsky, is available for consultations. Joseph E. Levi, Esq., can be reached via email at [email protected] or by phone at (212) 363-7500 for more personalized legal guidance.

No Out-of-Pocket Costs

If you are a potential class member, you may be entitled to compensation without incurring any upfront costs or legal fees. There is no financial burden associated with participating in this lawsuit.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securities litigation, Levi & Korsinsky has recovered substantial sums for harmed investors. The firm is highly regarded in this legal space, consistently ranking among the top securities litigation firms in the United States, indicating a significant track record of success and expertise.

For any investor in Regeneron concerned about their rights or potential losses, acting swiftly and seeking professional advice is crucial. This ongoing lawsuit represents not just a quest for compensation but also a stance against corporate misconduct that has damaged investor trust.